Alzheimer's Disease (AD)
Conditions
Keywords
Alzheimer's Disease (AD), Early Alzheimer's Disease, ABBV-916
Brief summary
Alzheimer's disease (AD) is a progressive, irreversible neurological disorder and is the most common cause of dementia in the elderly population. Clinical symptoms of the disease may begin with occasional forgetfulness such as misplacement of items, forgetting important dates or events, and may progress to noticeable memory loss, increased confusion and agitation, and eventually, loss of independence and non-responsiveness. This study will assess how safe and effective ABBV-916 is in treating early AD. Adverse events, change in disease activity, and how ABBV-916 moves through body of participants will be assessed. ABBV-916 is an investigational drug being developed for the treatment of early AD. This study is conducted in 2 stages. Stage A is a multiple ascending dose study. There is a 1 in 4 chance that participants are assigned to receive placebo. Stage B is a proof-of-concept study. In Stage B, there is a 1 in 5 chance that participants will be assigned to receive placebo. The first 6 months of this study are double-blind, which means that neither the trial participant nor the study doctors know which treatments will be given. This will be followed by a 2-year extension period in which all participants will receive ABBV-916. Approximately 195 participants aged 50-90 years will be enrolled in about 90 sites across the world. Participants will receive intravenous (IV) doses of ABBV-916 or placebo once every 4 weeks (Q4W) for 24 weeks and will be followed for an additional 16 weeks. Participants will have the option of participating in a 2-year, open-label, Extension Period receiving IV ABBV-916. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, magnetic resonance imaging (MRI), blood tests, checking for side effects and completing questionnaires.
Interventions
DRUGABBV-916
Intravenous administration
DRUGPlacebo
Intravenous administration
Sponsors
AbbVie
Study design
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
50 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
* Diagnosis of Stage 3 or Stage 4 Alzheimer's disease (AD) based on the 2018 National Institute on Aging (NIA)-Alzheimer's Association (AA) Research Framework Criteria. * Mini-Mental State Examination (MMSE) score of 20 to 28, inclusive, at Screening. * Blood-based biomarker results with a value consistent with amyloid positron emission tomography (PET) positivity. The biomarker will be chosen by the sponsor and described in the Laboratory Manual. Biomarker results will not be required for eligibility if the participant has a positive Amyloid PET scan meeting the central reader criteria. * Amyloid PET scan results consistent with amyloid pathology. * Stage B: Participants must have a study partner who spends a minimum average of 10 hours per week with the participant.
Exclusion criteria
* Significant pathological findings on brain MRI at screening including, but not limited to, evidence of vasogenic edema, 4 or more microhemorrhages, any macrohemorrhages, any superficial siderosis, or severe white matter disease. * Any anticoagulants or have a bleeding disorder that is not adequately controlled.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants Experiencing Adverse Events (AEs) | Up to approximately 160 weeks | An adverse event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study. |
| Stage A: Maximum Observed Serum Concentration (Cmax) for Multiple Ascending Dose of ABBV-916 | Up to approximately 24 weeks | Cmax of ABBV-916 will be determined. |
| Stage A: Time to Cmax (Tmax) for Multiple Ascending Dose of ABBV-916 | Up to approximately 24 weeks | Tmax of ABBV-916 will be determined. |
| Stage A: Apparent Terminal Phase Elimination Rate Constant (β) of ABBV-916 | Up to approximately 24 weeks | Apparent terminal phase elimination rate constant (β) of ABBV-916 will be determined. |
| Stage A: Terminal Phase Elimination Half-Life (t1/2) of ABBV-916 | Up to approximately 24 weeks | T1/2 of ABBV-916 will be determined. |
| Stage A: Trough Serum Concentration (Ctrough) of ABBV-916 at the End of a Dosing Interval | Up to approximately 24 weeks | Ctrough of ABBV-916 will be determined. |
| Stage A: Area Under the Concentration-Time Curve (AUC) of ABBV-916 | Up to approximately 24 weeks | AUC of ABBV-916 will be determined. |
| Stage A: Cerebrospinal Fluid (CSF) Concentration as a Measure of ABBV-916 Crossing the Blood Brain Barrier | Up to approximately 24 weeks | The central value for ratio of ABBV-916 concentration in cerebrospinal fluid (CSF) to that in serum will be estimated for evaluation of the fraction of ABBV-916 crossing the blood brain barrier. |
| Stage A: Percentage of Participants With Antidrug Antibodies (ADA) as a Measure of Immunogenicity Following Multiple Ascending Dose of ABBV-916 | Up to approximately 24 weeks | Antidrug antibody (ADA) classification and titers for positive ADA samples will be determined. |
| Stage B: Change in Brain Amyloid Plaque Deposition (Amyloid Centiloid Value) | Baseline (Week 0) through Week 24 | Change from baseline in brain amyloid plaque deposition (amyloid centiloid value) is measured by amyloid positron emission tomography (PET) scan. |
Countries
United States
Outcome results
None listed